Original Article

You have full text access to this OnlineOpen article

Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study†‡

  1. Thomas D. Schiano1,
  2. Michael Charlton2,
  3. Zobair Younossi3,
  4. Eithan Galun4,
  5. Timothy Pruett5,
  6. Ran Tur-Kaspa6,
  7. Rachel Eren7,
  8. Shlomo Dagan7,
  9. Neil Graham8,
  10. Paulette V. Williams8,
  11. John Andrews8,§,*

Article first published online: 24 AUG 2006

DOI: 10.1002/lt.20876

Issue

Liver Transplantation

Liver Transplantation

Volume 12, Issue 9, pages 1381–1389, September 2006

Additional Information

How to Cite

Schiano, T. D., Charlton, M., Younossi, Z., Galun, E., Pruett, T., Tur-Kaspa, R., Eren, R., Dagan, S., Graham, N., Williams, P. V. and Andrews, J. (2006), Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: Results of a phase 2 randomized study. Liver Transpl, 12: 1381–1389. doi: 10.1002/lt.20876

Author Information

  1. 1

    The Mt. Sinai School of Medicine, New York, NY

  2. 2

    Mayo Clinic, Rochester, MN

  3. 3

    Inova Fairfax Hospital, Falls Church, VA

  4. 4

    Hadassah University Hospital, Jerusalem, Israel

  5. 5

    University of Virginia, Charlottesville, VA

  6. 6

    Sackler School of Medicine Tel-Aviv University

  7. 7

    XTL Biopharmaceuticals Ltd., Rehovot, Israel

  8. 8

    XTL Biopharmaceuticals Inc., Durham, NC

  1. §

    Telephone: 910-200-5156; FAX: 910-458-2040

*XTL Biopharmaceuticals Inc., 2530 Meridian Pkwy., Suite 200; Durham, NC 27713

  1. †

    See Editorial on Page 1317

  2. ‡

    N.G., S.D., R.E., and J.A. are (or were at the time the work described was conducted) employees of XTL Biopharmaceuticals Inc. Otherwise, the investigators who conducted the study described herein received compensation for their involvement but have no proprietary or stock interest in XTL Biopharmaceuticals Ltd., other than that which might have been acquired through public transactions.

Publication History

  1. Issue published online: 24 AUG 2006
  2. Article first published online: 24 AUG 2006
  3. Manuscript Accepted: 22 MAY 2006
  4. Manuscript Received: 10 JAN 2006

Funded by

  • XTL Biopharmaceuticals Ltd.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (629K)

REFERENCES

  • 1
    Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival after liver transplantation for hepatitis C. Hepatology 1998; 28: 823–830.
    Direct Link:
  • 2
    Rodriguez-Luna H, Vargas HE. Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transpl 2005; 11: 479–489.
    Direct Link:
  • 3
    Morard I, Negro F. How should we treat recurrent hepatitis C after liver transplantation? J Hepatol 2005; 42: 462–468.
  • 4
    Samuel D. Antiviral treatment of recurrent hepatitis C after liver transplantation: The need for a multifaceted approach. Hepatology 2005; 41: 436–438.
    Direct Link:
  • 5
    Curry MP. Hepatitis B and hepatitis C viruses in liver transplantation. Transplantation 2004; 78: 955–963.
  • 6
    Shakil AO, McGuire B, Crippin J, Teperman L, Demetris AJ, Conjeevaram H, et al. A pilot study of interferon alpha and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002: 36: 1253–1258.
    Direct Link:
  • 7
    Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005: 42: 255–262.
    Direct Link:
  • 8
    Krawczynski K, Alter MJ, Tankersley DL, Beach M, Robertson BH, Lambert S, et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 1996; 173: 822–828.
  • 9
    Goto J, Nishimura S, Esumi M, Makizumi K, Rikihisa T, Nishihara T, et al. Prevention of hepatitis C virus infection in a chimpanzee by vaccination and epitope mapping of antiserum directed against hypervariable region 1. Hepatol Res 2001; 19: 270–283.
  • 10
    Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 1996; 93: 15394–15399.
  • 11
    Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 1994: 91: 7792–7796.
  • 12
    Eren R, Landstein D, Terkieltaub D, Nussbaum O, Zauberman A, Ben-Porath J, et al. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): A potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 2006: 80: 2654–2664.
  • 13
    Ilan E, Arazi J, Nussbaum O, Zauberman A, Eren R, Lubin I, et al. The hepatitis C virus (HCV)-Trimera mouse: A model for evaluation of agents against HCV. J Infect Dis 2002; 185: 153–161.
  • 14
    Dagan S, Eren R. Therapeutic antibodies against viral hepatitis. Curr Opin Mol Ther 2003; 5: 148–155.
  • 15
    Andrews J, Horton J, Dagan S, Eren, R, Terrault N, Galun E, et al. Changes in HCV RNA with monoclonal AB HCV-ABXTL-68 in patients with HCV infection. Hepatology 2004; 40: 514
  • 16
    Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York: J. Wiley; 1999: 117.
  • 17
    Honaker MR, Shokouh-Amiri MH, Vera SR, Alloway RR, Grewal HP, Hardinger KL, et al. Evolving experience of hepatitis B virus prophylaxis in liver transplantation. Transpl Infect Dis 2002; 4: 137–143.
    Direct Link:
  • 18
    Dienstag JL. Passive active immunoprophylaxis after percutaneous exposure to hepatitis B virus. Hepatology 1989; 10: 385–387.
    Direct Link:
  • 19
    Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with hepatitis B surface antigen. N Engl J Med 1993; 329: 1842–1847.
  • 20
    Charlton M. Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl 2003: 9: S58–S62.
    Direct Link:
  • 21
    Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa, M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002: 35: 680–687.
    Direct Link:
  • 22
    Powers KA, Ribeiro RM, Patel K, Painko S, Nyberg L, Pockros P, et al. Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl 2006: 12: 207–216.
    Direct Link:
  • 23
    Dahri H, Feliu A, Garcia-Retortillo M, Forns X, Neumann AU. Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. J Hepatol 2005: 42: 491–498.
  • 24
    Schiano T, Gutierrez JA, Walewski JL, Fiel MI, Cheng B, Bodenheimer H, et al. Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology 2005: 42: 1420–1428.
    Direct Link:
  • 25
    Neff GW, O'Brien CB, Cirocco R, Montalbano M, de Medina M, Ruiz P, et al. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing. Liver Transpl 2004; 10: 595–598.
    Direct Link:
  • 26
    Davis GL, Nelson DR, Terrault N, Pruett T, Schiano TD, Fletcher CV, et al. A randomized, open-label study to evaluate the safety and pharmacokinetics for human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005: 11: 941–949.
    Direct Link:
  • 27
    Shimizu YK, Hiroko I, Kiyhara T, Cabezon T, Farci P, Purcell, RH, et al. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 1996: 223: 409–412.
  • 28
    Bartosch B, Bukh J, Meunier J-C, Granier C, Engle RE, Blackwelder WC, et al. In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralizing epitopes. Proc Natl Acad Sci U S A 2003: 100: 14199–14204.
  • 29
    Yu MW, Bartosch B, Zhang P, Guo Z-P, Renzi PM, Shen L-M, et al. Neutralizing antibodies for hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A 2004: 101: 7705–7710.
  • 30
    Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Ree A, Hemming A, Howard R, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8: 1000–1006.
    Direct Link:
  • 31
    Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al. Interferon alpha 2-b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology 2003; 124: 642–650.
View Full Article (HTML) Get PDF (629K)